Search hospitals > Michigan > Monroe
Toledo Clinic Cancer Centers-Monroe
Claim this profileMonroe, Michigan 48162
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Pancreatic Cancer
Conducts research for Non-Small Cell Lung Cancer
148 reported clinical trials
6 medical researchers
Summary
Toledo Clinic Cancer Centers-Monroe is a medical facility located in Monroe, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer and other specialties. Toledo Clinic Cancer Centers-Monroe is involved with conducting 148 clinical trials across 263 conditions. There are 6 research doctors associated with this hospital, such as REX MOWAT, MD, Abhijit B. Saste, Jeffrey H. Muler, and Adam C. Walter.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage I
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
REX MOWAT, MDToledo Clinic Cancer Centers-Toledo2 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
79 reported clinical trials
151 drugs studied
Abhijit B. SasteProMedica Flower Hospital6 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
12 reported clinical trials
28 drugs studied
Jeffrey H. MulerProMedica Flower Hospital2 years of reported clinical research
Studies Bladder Cancer
Studies Prostate Cancer
11 reported clinical trials
33 drugs studied
Adam C. WalterProMedica Flower Hospital7 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Carcinoma
9 reported clinical trials
24 drugs studied
Clinical Trials running at Toledo Clinic Cancer Centers-Monroe
Lung Cancer
Cutaneous Melanoma
Pancreatic Carcinoma
Multiple Myeloma
Pancreatic Cancer
Esophageal cancer
Melanoma
Breast cancer
Breast Cancer
Non-Small Cell Lung Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Toledo Clinic Cancer Centers-Monroe?
Toledo Clinic Cancer Centers-Monroe is a medical facility located in Monroe, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer and other specialties. Toledo Clinic Cancer Centers-Monroe is involved with conducting 148 clinical trials across 263 conditions. There are 6 research doctors associated with this hospital, such as REX MOWAT, MD, Abhijit B. Saste, Jeffrey H. Muler, and Adam C. Walter.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.